Resmetirom MASH treatment represents one of the most significant advances in liver disease research in recent years. The FDA has approved Resmetirom, previously known as MGL-3196 and now marketed as Rezdiffra, as the first oral medication specifically targeting metabolic dysfunction associated steatohepatitis, or MASH, in adults with non-cirrhotic disease and moderate to advanced fibrosis. For the millions of patients living with fatty liver disease and the clinical researchers working to address it, this approval marks a meaningful turning point.
FOMAT supports digestive disease clinical research nationally, connecting patients with access to emerging treatments through its active clinical trial network.
Why MASH has become a urgent global health priority
Metabolic dysfunction associated steatotic liver disease, known as MASLD and commonly referred to as fatty liver disease, now affects more than 30 percent of adults worldwide. In regions like South America and the Middle East, prevalence rates reach 40 to 45 percent. The condition progresses in a subset of patients to MASH, a more severe inflammatory form that accelerates liver damage and significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver related mortality.
MASLD has become a leading cause of liver transplants in many Western countries. Despite the scale of the problem, effective pharmacological treatments have been lacking for decades, making the approval of Resmetirom MASH treatment a watershed moment for hepatology and for the patients who need options.
The connection between thyroid hormones and fatty liver disease
The development of Resmetirom as a MASH treatment is rooted in research uncovering the relationship between thyroid hormone function and liver fat metabolism. Primary hypothyroidism is known to increase the risk of MASLD and MASH, and evidence suggests the two conditions may be directly connected through shared biological mechanisms.
Even in patients with normal thyroid levels, severe liver disease can cause the liver to convert thyroid hormone T4 into an inactive form rather than the active T3 form. Patients with MASH frequently show reduced thyroid hormone effectiveness in the liver, limiting the organ’s ability to regulate fat metabolism efficiently. Studies examining liver biopsies from patients with suspected MASH found that even those with low normal thyroid function showed increased probability of a MASLD diagnosis and higher liver fibrosis scores.
These findings encouraged researchers to explore thyroid hormone based therapies. Remarkably, treatment with ultra low doses of levothyroxine was able to reduce liver lipid content in patients with type 2 diabetes and MASLD without producing changes in circulating hormone levels, confirming that thyroid hormones play a meaningful role in reducing fat accumulation in the liver.
How Resmetirom MASH treatment works
Resmetirom is a liver targeted thyroid hormone receptor beta selective agonist, meaning it activates thyroid hormone receptors specifically in the liver while minimizing systemic effects. This targeted mechanism allows it to reduce liver fat and fibrosis without the cardiovascular and bone related risks associated with systemic thyroid hormone therapy.
The drug is administered orally once daily, making it significantly more convenient than injectable or infusion based therapies. This ease of administration is important for long term treatment adherence in a patient population that frequently manages multiple chronic conditions simultaneously.
According to the Mayo Clinic, nonalcoholic fatty liver disease and its more severe forms affect people of all ages and are closely linked to obesity, type 2 diabetes, and metabolic syndrome, underlining the scale of the unmet need that Resmetirom addresses.
What clinical studies showed about Resmetirom
The clinical evidence supporting Resmetirom MASH treatment is substantial and spans multiple study populations. In an initial study, 125 overweight or obese adults with biopsy confirmed MASH received Resmetirom 80 mg daily. The treatment outperformed placebo in reducing liver fat, with greater benefit observed with longer duration of use. Beyond fat reduction, Resmetirom also lowered liver enzyme levels and markers of liver fibrosis. Patients who demonstrated liver fat and tissue improvements also reported meaningful gains in overall health and quality of life.
A larger confirmatory study involving 966 obese adults validated these findings across a longer treatment period, establishing that the benefits observed in the initial trial were durable and reproducible at scale. These results formed the basis for the FDA’s approval and established Resmetirom as a clinically meaningful option for a patient population with limited alternatives.
What comes next for Resmetirom and MASH research
The FDA’s conditional approval of Resmetirom MASH treatment covers adults with non-cirrhotic MASH and moderate to advanced fibrosis. Ongoing research will determine whether the drug also reduces broader liver related complications including cirrhosis, liver transplant need, hepatocellular carcinoma, and overall mortality, rather than addressing cellular fatty infiltration alone.
Given the complexity of MASLD and its impact across multiple organ systems, future treatment approaches may combine Resmetirom with complementary therapies that address cardiovascular and metabolic complications alongside the liver disease itself. This evolving treatment landscape will require continued clinical investigation across Phase II through Phase IV trials. FOMAT supports that research nationally through its digestive disease clinical trial capabilities and its Phase I through Phase IV research infrastructure.
Participate in MASH clinical trials with FOMAT
If you or a loved one has been diagnosed with MASH or fatty liver disease, participating in a clinical trial may provide access to emerging treatments while contributing to research that can benefit future patients. FOMAT is actively conducting MASH trials nationally, and eligible participants may receive compensation for their time and travel. Visit FOMAT’s active studies page to learn more and find out if you qualify.